Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990775 | 0.86 | MAPK14 (0.56) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL4994474 | 0.84 | MAPK14 (0.52) | EPHX2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4992970 | 0.84 | PARP10 (0.51) | NPC1RAB9AALDH1A1MAPTHPGD | |
| SCHEMBL4985848 | 0.82 | OPRM1 (0.51) | HPGD | |
| SCHEMBL4995830 | 0.81 | ACACB (0.47) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL4989136 | 0.81 | CYP3A4 (0.48) | EPHX2NR4A2 | |
| SCHEMBL4995481 | 0.81 | CYP2C9 (0.56) | EPHX2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7457448 | 0.81 | SRD5A2 (0.47) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL8364280 | 0.80 | EPHX1 (0.45) | EPHX2 | |
| SCHEMBL5010339 | 0.79 | S1PR1 (0.44) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | claimed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | claimed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | claimed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | claimed |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | PURDUE PHARMA L.P. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7393872-B2 | Sodium channel blocker compositions and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-07-01 | — | — | US | disclosed |
| EP-1169060-B1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2005-08-31 | — | — | EP | disclosed |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | disclosed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | ESRRG 3444/4885NR1H4 1325/4885EPHX2 2152/4885 |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | CACNA1B, CACNB2, CACNA1C | ESRRG 3444/4885NR1H4 1325/4885EPHX2 2152/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | ESRRG 3444/4885NR1H4 1325/4885EPHX2 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.